eXoZymes raises $639,990 to advance its NCT biotech platform
What's the deal? eXoZymes, a Nasdaq-listed biotech firm developing its proprietary N-trans-caffeoyltyramine (NCT) technology, has closed a $639,990 underwritten offering of common stock and warrants.
The Nevada-based company sold 71,110 shares and 35,555 warrants, each entitling the holder to buy one more share.
Net proceeds — after $44,799 in underwriting commissions and roughly $30,000 in expenses — will fund NCT product development, research, working capital, and general corporate needs.
Why now? The offering closed on June 30, 2026, under a shelf registration statement declared effective in January 2026.
As an emerging growth company, eXoZymes is tapping public markets to accelerate its NCT pipeline and fund next-in-line products.
What could go wrong? eXoZymes acknowledged that issuing new shares and warrants may dilute existing shareholders.
The bet: capital raised now could lift long-term value if eXoZymes delivers on its development plans. Its stock remains listed on Nasdaq, with no delisting actions anticipated.
The signal: The modest raise underscores how early-stage biotechs like eXoZymes lean on shelf registrations to pull in capital quickly and in tranches. For a company betting on NCT technology to reshape drug discovery, every dollar now goes toward proving the science and keeping its pipeline moving.
Read more: MiniChart
Image credit: Idaho National Laboratory
